Recent developments in disease modifying therapies have been proven to slow the progression of cognitive decline associated with Alzheimer’s disease.
And yet, we can only confirm a diagnosis of AD after a patient’s death.
But what if we could use biomarkers to identify preclinical stage Alzheimer’s and step in long before a patient exhibits dementia?
On this episode of Inside the Lab, your host, Ms. Kelly Swails, MT(ASCP) introduces us to Dr. Shih-Hsiu Jerry Wang, MD, PhD, Assistant Professor of Pathology and Assistant Professor of Neurology at the Duke University School of Medicine, and shares his talk on emerging biomarkers for the assessment of Alzheimer’s disease from the ASCP 2023 Annual Meeting.
Dr. Wang explains how we measure AD right now and why there’s discordance between the clinical presentation and pathology of Alzheimer’s.
Dr. Wang walks us through the core biomarkers for identifying AD per the AT(N) framework, describing the pros and cons of current detection methodologies and offering recommendations around when to use blood biomarkers versus PET imaging or CSF.
Listen in for insight into the ongoing search for better AD biomarkers and learn what we are doing to diagnose Alzheimer’s in its early stages and intervene accordingly.
Topics Covered
· The clinical definition of Alzheimer’s disease and how it impacts cognitive function
· How we measure Alzheimer’s in pathology by amyloid plaques and neurofibrillary tangles
· Why there’s discordance between the clinical presentation and pathology of AD
· The core biomarkers for identifying Alzheimer’s disease per the AT(N) framework
· Identifying the stages of AD based on amyloid plaque, pathologic tau and neurodegeneration
· Examples of PET imaging for the different stages of AD and how imaging biomarkers predict cognitive decline
· The limitations of fluid biomarkers vs. imaging biomarkers to detect Alzheimer's disease
· Some of the emerging ultrasensitive biomarker detection methods in development for AD
· Using cerebral spinal fluids (CSF) vs. plasma biomarkers to identify Alzheimer's disease
· A comparison of the mass spectrometry vs. SIMOA methods of analyzing p-tau biomarkers
· Why Dr. Wang suggests blood biomarkers for AD screening (with confirmation by PET or CSF)
· Why SNAP-25, NfL and GFAP are not considered core biomarkers for Alzheimer’s disease
· The ongoing search for better biomarkers and ultrasensitive detection methods for AD
Connect with ASCP
ASCP
ASCP on Facebook
ASCP on Instagram
ASCP on Twitter
Connect with Dr. Wang
Dr. Wang at Duke University
Connect with Ms. Swails
Ms. Swails on Twitter
Resources
Dr. Wang’s Slides from the ASCP Annual Meeting 2023
‘NIA-AA Research Framework: Toward a Biological Definition of Alzheimer’s Disease’ in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association
Inside the Lab in the ASCP Store
Ep18: Lab Week Games and the Importance of Celebrating the Lab
Ep17: COVID-19 Patients: The Lab Saved My Life
Ep16: COVID-19 Vaccine Safety
Ep15: Getting People in the Seats: Recruitment for MLS Programs
Ep14: Infectious Disease as a Bridge Between Anatomic Pathology and Clinical Pathology
Ep13: Laboratory Staffing Shortages
Ep12: Transgender Pathology
Ep11: Mentorship in the Laboratory
Ep10: The Importance of Empowered Patients
Ep09: Native American-Specific Challenges with COVID-19
Ep08: The Laboratory's Role in Inclusion
Ep07: Forensic Pathology and Patient Advocacy during COVID-19
Ep06: Research and Publication
Ep05: Laboratory Turnaround Times During COVID-19
Ep04: Burnout in the Lab
Ep03: Online Teaching and Learning in Pathology and Laboratory Medicine
Ep02: The Impact of COVID-19 on Community Hospitals and MLS Programs
Ep01: Disparities in COVID-19 Cases Among Minorities
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.